title: Idarubicin in acute leukaemia. GIMEMA Group.
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: L
authors.initials: L
authors.lastname: Annino
authors.forename: G
authors.initials: G
authors.lastname: Avvisati
authors.forename: F
authors.initials: F
authors.lastname: Giona
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: A M
authors.initials: AM
authors.lastname: Testi
authors.forename: A M
authors.initials: AM
authors.lastname: Carella
authors.forename: F
authors.initials: F
authors.lastname: Caronia
authors.forename: M
authors.initials: M
authors.lastname: Carotenuto
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
chemical_list: D003561:Cytarabine; D015255:Idarubicin